Skip to search formSkip to main contentSkip to account menu

Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells

Known as: Anti-CD3 x CD20Bi-Armed ATC 
Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
Targeting HER2 overexpressed breast cancer cells with anti‑HER2 monoclonal antibodies inhibits tumor growth. Here we investigated… 
2014
2014
Abstract 2806: A phase Ia/Ib trial of chemotherapy followed by infusions of activated T cells armed with OKT3 x trastuzumab bispecific antibody, IL-2 and GM-CSF for stage II/ III, Her2+ or Her2- high…
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Anti-CD3 x anti-HER2Bi bispecific antibody… 
2014
2014
Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients.
3073 Background: : Despite improvements in the treatment of metastatic breast cancer (MBC), there are no curative treatment… 
2012
2012
Pan-Bcl-2 Inhibitor AT-101 Enhances Tumor Cell Killing by EGFR Targeted T Cells
Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and… 
2011
2011
T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment of women with stage IV breast cancer (phase I): Clinical and immune function results.
2548 Background: Nontoxic immunologic targeting strategies for the treatment of metastatic breast cancer (MBC) are needed. Anti… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)